CEP 11981

Drug Profile

CEP 11981

Alternative Names: CEP-11981; SSR 106462

Latest Information Update: 15 Mar 2016

Price : $50

At a glance

  • Originator Cephalon; sanofi-aventis
  • Developer Sanofi; Teva Pharmaceutical Industries
  • Class Antineoplastics; Carbazoles; Pyrimidines
  • Mechanism of Action TIE 2 receptor antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 09 Nov 2007 Data presented at the 19th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2007) added to the adverse events and Cancer pharmacodynamics sections
  • 09 Nov 2007 Phase-I clinical trials in Solid tumours in USA (PO)
  • 20 Dec 2001 Preclinical trials in Solid tumours in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top